- Home
- SRTS vs ATYR Comparison
SRTS vs ATYR Comparison
Compare SRTS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | ATYR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | 60 | 58 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 50.9M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRTS | ATYR |
|---|---|---|
| Price | $3.19 | $0.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $7.00 | $3.67 |
| AVG Volume (30 Days) | 72.2K | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $34.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.82 | $0.40 |
| 52 Week High | $5.92 | $7.29 |
Technical Indicators
Market Signals| Indicator | SRTS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 37.89 |
| Support Level | $3.03 | $0.40 |
| Resistance Level | $3.53 | $0.86 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 23.97 | 15.80 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).